Kisspeptin-10 vs MK-677 (Ibutamoren)
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Kisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profileMK-677 (Ibutamoren)
Oral non-peptide growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release without injection. Long half-life (~24 hours) enables once-daily oral dosing. Widely researched for body composition, sleep quality, and IGF-1 elevation.
Full profile| Kisspeptin-10 | MK-677 (Ibutamoren) | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | KP-10, Metastin(112-121), KISS1R agonist | Ibutamoren, Nutrobal, MK677, L-163,191 |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) | 10mg–50mg mg, once daily oral |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) | Oral (capsule/liquid) |
| Key side effects | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing | Water retention, Increased appetite, Elevated fasting glucose (long-term), Fatigue (initial, transient) |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: Kisspeptin-10 is fda-approved, while MK-677 (Ibutamoren) is research-stage.
- Administration: Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses); MK-677 (Ibutamoren) — Oral (capsule/liquid).
- Dosing units differ: Kisspeptin-10 is dosed in mcg, MK-677 (Ibutamoren) in mg — they operate at different scales.
- Frequency: Kisspeptin-10 is typically 1–2x daily (pulsatile administration is important — avoid continuous infusion); MK-677 (Ibutamoren) is once daily oral.
- Research depth: this profile cites 3 sources for Kisspeptin-10 vs 2 for MK-677 (Ibutamoren).
How each works
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
MK-677 (Ibutamoren)
MK-677 binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile GH release and increase circulating IGF-1. Unlike peptide GHRPs it survives oral administration. Clinical trials demonstrate significant increases in GH pulsatility and IGF-1 without suppression of the endogenous GH axis, though long-term use raises glucose metabolism concerns.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.